Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alzheimer’s disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden.
Metrics to compare | ALZ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALZPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.4x | −9.6x | −0.5x | |
PEG Ratio | −0.21 | −0.20 | 0.00 | |
Price/Book | 1.1x | 6.6x | 2.6x | |
Price / LTM Sales | 6.8x | 42.3x | 3.3x | |
Upside (Analyst Target) | 263.5% | 10.2% | 43.5% | |
Fair Value Upside | Unlock | 6.3% | 6.9% | Unlock |